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Abstract
Background: Healthcare decisionmaking is a complex process relying on disparate types of
evidence and value judgments. Our objectives for this study were to develop a practical framework
to facilitate decisionmaking in terms of supporting the deliberative process, providing access to
evidence, and enhancing the communication of decisions.
Methods:  Extensive analyses of the literature and of documented decisionmaking processes
around the globe were performed to explore what steps are currently used to make decisions with
respect to context (from evidence generation to communication of decision) and thought process
(conceptual components of decisions). Needs and methodologies available to support
decisionmaking were identified to lay the groundwork for the EVIDEM framework.
Results: A framework was developed consisting of seven modules that can evolve over the life
cycle of a healthcare intervention. Components of decision that could be quantified, i.e., intrinsic
value of a healthcare intervention and quality of evidence available, were organized into matrices.
A multicriteria decision analysis (MCDA) Value Matrix (VM) was developed to include the 15
quantifiable components that are currently considered in decisionmaking. A methodology to
synthesize the evidence needed for each component of the VM was developed including electronic
access to full text source documents. A Quality Matrix was designed to quantify three criteria of
quality for the 12 types of evidence usually required by decisionmakers. An integrated system was
developed to optimize data analysis, synthesis and validation by experts, compatible with a
collaborative structure.
Conclusion:  The EVIDEM framework promotes transparent and efficient healthcare
decisionmaking through systematic assessment and dissemination of the evidence and values on
which decisions are based. It provides a collaborative framework that could connect all
stakeholders and serve the healthcare community at local, national and international levels by
allowing sharing of data, resources and values. Validation and further development is needed to
explore the full potential of this approach.
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Background
The objective of any healthcare intervention is to improve
health; preventive measures, non-pharmacological and
pharmacological treatments, and medical procedures are
among the numerous available options. Decisionmaking
in healthcare is a complex process taking place along a
continuum that moves from evidence generation to delib-
eration on each particular intervention and communica-
tion of the resultant decision.
Evidence-based medicine and evidence-informed health
policymaking rely on evidence generated by developers of
healthcare interventions, at least in the initial stages of the
life cycle of an intervention. Evidence quantity, quality,
usability and accessibility have been identified as hin-
drances to informed policymaking,[1] highlighting the
disconnect between those who need evidence to make a
decision and those who generate this evidence. Beyond
evidence, decisionmaking requires value judgment. [2,3]
Tunis argues that controversy around decisions may stem
from the absence of shared views about the role of evi-
dence versus judgment in evidence-based healthcare poli-
cies.[3]
Frequent controversy surrounding drug coverage variation
across jurisdictions with similar levels of economic devel-
opment, values and political systems [4-7] highlights a
need for rational and transparent approaches to decision-
making. Surveys have recognized a need for fair and
explicit healthcare decisionmaking processes that are
more defensible.[8,9]
Such processes should fulfill two main functions. Firstly,
they should support the complex deliberative process that
requires simultaneous consideration of multiple factors
such as clinical benefit,[10] level of innovativeness,[6,10]
quality of clinical evidence,[4,10] quality of dossier [i.e.,
organization, accuracy of information presented],[10]
cost-effectiveness,[10,11] price and budget impact,[6,10]
value judgments,[10] and colloquial evidence [anything
that establishes a fact or gives reason for believing some-
thing].[12] Without an explicit process to structure such
complex deliberation, decisionmakers are likely to resort
to intuitive and subjective approaches, potentially miss-
ing important information.[13]
Secondly, such processes should help legitimize the deci-
sion by ensuring that conditions for 'accountability for
reasonableness' (A4R) are met by structuring the deliber-
ative process to make rationale and principles on which
decisions are based explicit and ultimately publicly avail-
able. Within the A4R framework, availability to public
scrutiny is a necessary prerequisite to legitimizing deci-
sions.[14] As suggested by Dhalla and Laupacis, transpar-
ency in all areas of healthcare policymaking, including
availability of data and decisionmaking rationales, is
likely to raise public confidence in the process and may
ultimately lead to better decisions.[15]
Several approaches have been published for making
healthcare coverage decisionmaking more consistent,
rational and transparent. [16-19] For example, the Cancer
Care Ontario Policy Advisory Committee developed a
tool that supports the deliberative process by presenting
structured synthesized information on various aspects of
the drugs considered.[17] A number of UK Health Author-
ities have developed explicit multicriteria models to facil-
itate prioritization decisions.[18] These attempts
highlight growing awareness in those at the forefront of
decisionmaking, and others in the field, of the need for a
more holistic approach that goes beyond reliance on cost-
effectiveness criteria. [20-23]
In this context, we hypothesized that healthcare decision-
making could be facilitated by structuring access, consid-
eration and communication of the evidence and the value
judgments on which it is based. The objective of this study
was to develop a practical framework to facilitate deci-
sionmaking by supporting the deliberative process, per-
mitting access to relevant evidence, and enhancing
effective communication of decisions.
Methods
Extensive analyses of the literature and of current deci-
sionmaking processes were performed to identify steps
leading to decisions, as well as the components of the
thought processes underlying decisions. Needs and meth-
odologies available to support such processes were identi-
fied to lay the groundwork on which to build the EVIDEM
framework.
Review of decisionmaking processes in jurisdictions
worldwide [10,24-44] was performed to explore the con-
tinuum from evidence generation to decision, to commu-
nication of decision. Processes for drug coverage decisions
were used as a model since they are often the most struc-
tured and explicit in healthcare decisionmaking; however,
all analyses were performed from the perspective of facil-
itating decisions for any type of healthcare intervention.
Based on this review, the current steps flow as follows: (1)
manufacturers/innovators generate data with experts and
submit evidence to the decisionmaking body following
specific requirements; (2) assessors & reviewers collect
and appraise evidence (quality assessment), prepare a
report for a decision committee (synthesized evidence)
and may incorporate stakeholder opinion; (3) a commit-
tee makes a decision based on that report and stakeholder
opinion; (4) the decision is made public with rationale for
decision; an appeal process may be in place. Drawing
from this analysis, the following needs were identified:BMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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 systematic and explicit consideration of all key elements
of decision during the deliberative process;[17,18]
 each committee member's perspective needs to be cap-
tured and values shared in the committee;[16,45]
 relevant evidence in a digested, unbiased and systematic
format;[16,17]
 data on quality of evidence in a structured system for all
types of evidence considered;[18] and
 transparent, understandable, and acceptable communi-
cation of decision.[15,41]
These needs were all considered in developing the frame-
work. Analysis of the literature revealed that decisionmak-
ing can broadly be subdivided into scientific judgment
and value judgment.[2,3]
Scientific judgment relies on globally accepted standards
defining the quality of evidence. Such technical judgment
can be applied using a system in which the elements of
quality are explicitly identified and quantified (scored).
Scientific technical judgments are not highly dependent of
the evaluator (compared to value judgments) and can be
standardized. A number of quality standards, country spe-
cific guidelines, checklists and instruments are available
to assess the quality of various types of evidence (e.g.,
CONSORT,[46] CHEC,[47] STROBE[48], QUOROM[49],
MOOSE[50],. GRADE[51,52], QHES[53,54] and others
[24-27,29-40,55-67]). While these provide a rigorous sci-
entific basis for quality assessment of evidence, additional
elements were identified that could integrate scientific
judgment into a practical approach to healthcare deci-
sionmaking. These include:
 streamlining quality assessment for all types of evidence;
 distinguishing between quality of reporting, and rele-
vance and validity of evidence;
 providing the rationale behind scoring for full transpar-
ency; and
 using systematic deliberative processes to collaboratively
evaluate the quality of evidence.
Analysis of the literature on quantifiable tools for value
judgments considered in decisionmaking pointed to mul-
ticriteria decision analysis (MCDA). MCDA structures the
deliberative process by breaking down a problem into the
components expected to impact the value of an option,
and by quantifying them using a scale with defined
anchors.[13,68] MCDA explores value judgment from
two standpoints: the value system of the evaluator with
regard to the importance of each value components
(weights) and the actual performance of an intervention
(scores). A value estimate is obtained by combining
weights and scores using simple or complex mathematical
models. MCDA is widely used to support decisions in
environmental engineering, agriculture, and market-
ing[13] and is a promising approach to healthcare deci-
sionmaking [69-74].
Review of decisionmaking processes revealed that not all
value components usually considered in decisionmaking
are readily quantifiable.[10,24-44,61-67] A commonly
shared direction of scoring is needed to define low and
high ends of a scale to make quantification meaningful. In
general, components defining the intrinsic value of an
intervention are quantifiable from a universal standpoint,
while extrinsic or system-related components are not
readily quantifiable or quantification scales depend on
specific local considerations. For example, when consider-
ing the intrinsic value component "improvement of effi-
cacy", it is generally agreed that, all else being equal, an
intervention that brings major efficacy improvement has
a higher value than one with minor improvement. How-
ever, components such as historical context, stakeholder
pressure, population priorities and access, and ability of a
healthcare system to make appropriate use of interven-
tion, factors often critical in healthcare deci-
sions,[41,75,76] do not have consistent impact on how an
intervention is valued. For these components, what con-
stitutes increase or decrease in value requires definition
during deliberation at the jurisdictional level and on a
case-by-case basis. Consideration of extrinsic components
is easier once intrinsic value components have been
defined.
To facilitate value judgments related to a healthcare inter-
vention, following needs were identified:
 disentangle intrinsic and extrinsic value compo-
nents;[75,76]
 develop a simple and rigorous system that applies
MCDA from a pragmatic standpoint based on actual
thought processes;
 provide practical access to the evidence on which value
judgments are based; and
 provide a practical method for decisionmakers to pro-
vide feedback to data producers and all other stakehold-
ers.
Thus identified, these needs were used to develop the EVI-
DEM framework, processes and tools.BMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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Results
Framework
A practical framework was developed structuring and
making more shareable what is currently being done
around the world. It was based on three main principles:
 Support deliberative process by disentangling and quan-
tifying when possible scientific judgment (quality of evi-
dence) and value judgment (intrinsic and extrinsic value
of intervention);
 Facilitate access to relevant evidence over the life cycle of
a healthcare intervention using a collaborative structure;
and
 Enhance communication of decisions using transparent
tools.
The framework structures the context of decisions for a
healthcare intervention in a given setting into seven mod-
ules (Figure 1). The centerpiece of the framework is the
MCDA Value Matrix (module 5) which is both a quantifi-
cation tool for the intrinsic value of an intervention and a
portal to evidence (synthesized [module 3] with elec-
tronic links to full text source information [module 2])
and to data on quality of evidence (module 4 – Quality
Matrix). Extrinsic value is considered in module 6 and
communication of the decision is module 7. Applying the
full framework from the early stage of development of a
healthcare intervention requires a collaborative approach
(module 1) in which all stakeholders are involved, i.e.,
decisionmakers, experts, data assessors and data produc-
ers. The result of the process is an EVIDEM record, mod-
ules of which can be shared in a web-based collaborative
database for transparency and application by other deci-
sionmaking groups or individuals. The modular aspect
facilitates access to evidence and decisions, updates, and
database development.
Value of intervention – Value Matrix
A MCDA Value Matrix (VM) was developed to include the
value components usually considered in policy decision-
making. MCDA was selected as a methodological model
for the VM for its versatility, transparency and ease of
Conceptual framework for healthcare decisionmaking in a given setting Figure 1
Conceptual framework for healthcare decisionmaking in a given setting.
07 - Decision
06 - Extrinsic 
value
02 - Evidence available
01 - EVIDEM Team
Healthcare intervention in a given setting
04 - Quality of 
evidence
Quality Matrix
03 -
Synthesized 
evidence
05 - Intrinsic 
value 
MCDA Value MatrixBMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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application by a wide range of stakeholders. Value com-
ponents that can not be readily incorporated into a matrix
were not included and were listed as extrinsic components
for consideration at the jurisdictional level or on a case-
by-case basis (e.g., equity, historical context, stakeholder
pressure, population priorities and access, ability of
healthcare system to make appropriate use of interven-
tion) (module 6).
The VM (module 5) was designed to address the key ques-
tion: What is the value of a healthcare intervention with
respect to its intrinsic characteristics? In other words, what
does it bring to the health of society (for the jurisdiction
being considered)? Such a question involves probing the
value system of decisionmakers (weights) and assessing
the healthcare intervention based on evidence available
using defined scales (scores). The value estimate of an
intervention is the combination of weights and scores.
Components of decisionmaking identified in the analysis
of current decisionmaking processes were specifically
defined and structured to fulfill MCDA methodological
requirements.[68] These are:
￿ Completeness: all currently-understood components
defining the intrinsic value of an intervention are
included;
￿ Non-redundancy: all components are necessary, impor-
tant and there are no duplicates;
￿ Mutual independence: scoring of each component is
independent from scoring of all other components (i.e.,
scores for each component can be assigned without con-
sidering scores for other components); and
￿ Operationality: each component is defined unambigu-
ously; data on which to base the evaluation is available;
the numerical scale follows a shared sense of direction.
Fifteen components were thus defined and grouped into
four clusters; scoring directions were defined from a soci-
etal perspective (Figure 2)[68]. The first cluster assesses
the impact of the quality of evidence on the value of an
intervention (e.g., how the relevance and validity of evi-
dence impacts the value of an intervention). This is not to
be confused with the assessment of the quality of evi-
dence, which is performed separately using the Quality
Matrix (QM, see below). One key principle of EVIDEM is
that reasoning is facilitated and made more objective by
disentangling these distinct concepts (quality of evidence
based on scientific standards versus the value assigned to
the quality of evidence). The first cluster was broken down
into three components corresponding to the three criteria
of the QM.
The disease impact cluster was broken down into two
components: disease severity (D1) and size of affected
population (D2). It was assumed that an intervention for
a very severe disease has more value than an intervention
for a mild disease (D1) and that an intervention that ben-
efits a large number of patients has more value than one
that benefits a small number of patients (D2).
The intervention cluster was broken down into seven
components. The first (I1) explores the impact of clinical
guidelines. Clinical guidelines serve multiple functions
for numerous groups and have become ubiquitous.[77]
They can have considerable impact on practice and per-
ceived value of an intervention.[78] It was assumed that
guidelines represent current consensus and that strong
(e.g., Class I)[79] recommendations for the intervention
under consideration or for a similar intervention (e.g., a
product structurally related[80]) would result in a high
value score. The second component assesses the impact of
limitations of current interventions (I2) on the value of a
new intervention.
The concept of improvement of medical service, used by
the Commission de la Transparence in France,[81] was
used to define three key components of the value of an
intervention: efficacy and effectiveness (I3); safety and tol-
erability (I4); and patient reported outcomes, conven-
ience and adherence (I5). Assessing these components
required clearly defining which existing medical services
and medical practices the new treatment is meant to
replace or complement. Data for these existing services
provides the evaluator with an evidence-based frame of
reference for components I3 to I5. Components I6 "Public
health interest" and I7 "Type of medical service" capture
the nature of the health benefit of the intervention respec-
tively at the population level and at the individual level.
The economics cluster was broken down into three com-
ponents to explore the impact of covering a new interven-
tion on health plan budgets (E1), on other spending (E3),
and its cost-effectiveness (E2). To ensure non-redundancy
and to be in line with standard budget impact modeling
practices, components E1 and E3 respectively were
defined to cover financial impact of intervention only
(limited to the cost of intervention and potential savings
in replacement of existing interventions) and all other
economic impacts (such as those resulting from changes
in hospitalization, adverse events, disability, equipment
maintenance cost). The latter is usually explored in eco-
nomic evaluations, which are made more useful to deci-
sionmakers by reporting disaggregated cost-consequence
information.[82] The economic evaluation component
(E2) assesses the value of an intervention based on cost-
effectiveness ratios obtained from the analytic perspec-
tives (e.g., healthcare system, societal). Although thisBMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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Value Matrix – definitions of components and scoring scales Figure 2
Value Matrix – definitions of components and scoring scales.
Cluster 
Components of value 
assessment (alphabetical by 
cluster) 
Definition 
Scoring scale 
Low value                                  High value 
Quality of evidence      
Q1  Adherence to requirements of 
decisionmaking body 
Extent to which evidence on the proposed intervention submitted to a 
decisionmaking body fulfills requirements of that body with respect to the 
type of evidence to be provided, level of detail to be presented, sources to 
be supplied/indicated etc. 
 
Low adherence                   High  adherence 
Q2  Completeness and consistency 
of reporting evidence  
Extent to which reporting of evidence on the proposed intervention is 
complete (i.e., meeting international standards on reporting) and consistent 
with the sources cited 
 
Many gaps /                            Complete and 
inconsistent                                consistent  
Q3  Relevance and validity of 
evidence 
Extent to which evidence on the proposed intervention is relevant to the 
decisionmaking body (in terms of population, disease stage, comparator 
interventions, outcomes etc.) and valid with respect to international 
standards (i.e., study design etc.) and conclusions (agreement of results 
between studies) 
 
Low relevance /                  High relevance / 
    validity                                       validity  
Disease impact     
D1  Disease severity 
Severity of the health condition targeted by the proposed intervention with 
respect to mortality, disability, impact on quality of life, clinical course (i.e., 
acuteness, clinical stages) 
 
      Not severe                           Very severe 
(minor inconvenience) 
D2  Size of population affected by 
disease 
Number of people affected by the condition (targeted by the proposed 
intervention) among a specified population at a specified time; can be 
expressed as annual number of new cases (annual incidence) and/or 
proportion of the population affected at a certain point of time (prevalence) 
 
Very rare disease             Common disease 
Intervention     
I1  Current clinical guidelines 
Concurrence of the proposed intervention (or similar alternatives) with the 
current consensus of a group of experts on what constitutes state-of-the-
art practices in the management of the targeted health condition; 
guidelines are usually developed via an explicit process and are intended 
to improve clinical practice 
 
         No                                     Strong  
recommendation               recommendation 
I2  Current interventions’ limitations 
Shortcomings of current interventions in their ability to prevent, cure, or 
ameliorate the condition targeted by the proposed intervention; also 
includes shortcomings with respect to safety, convenience or patient 
acceptance 
 
  No or very                         Major limitations 
minor limitations 
I3  Improvement of 
efficacy/effectiveness 
Capacity of the proposed intervention to produce a desired (beneficial) 
change in signs, symptoms or course of the targeted condition above and 
beyond beneficial changes produced by alternative interventions. Includes 
efficacy and effectiveness data, as available 
 
Lower efficacy/                                Major 
   effectiveness                         improvement 
than comparators                      in efficacy/ 
     presented                           effectiveness 
I4  Improvement of safety & 
tolerability 
Reduction in intervention-related health effects that are harmful or 
undesired compared to alternative interventions 
 
    Lower safety/                              Major 
       tolerability                          improvement 
than comparators                        in safety/  
      presented                             tolerability 
I5 
Improvement of patient reported 
outcomes, convenience & 
adherence 
Capacity of the proposed intervention to produce beneficial changes in 
patient-reported outcomes (PROs) (e.g., quality of life) above and beyond 
beneficial changes produced by alternative interventions; also includes 
improvement in convenience to patients and adherence to treatment 
course 
    Worse PROs / 
lower convenience/                        Major  
  lower adherence                    improvement   
  than comparators  
       presented 
I6  Public health interest 
Nature of the health benefit provided by the proposed intervention at the 
population-level (e.g., impact on prevention, reduction in disease 
transmission, reduction in the prevalence of risk factors, etc.) 
 
No risk reduction           Major risk reduction 
 
I7  Type of medical service 
Nature of the clinical benefit provided by the proposed intervention at the 
patient-level (e.g., symptom relief, prolonging life, cure, diagnostic, 
prevention etc.) 
 
Minor service                           Major service 
Economics     
E1  Budget impact on health plan 
Net impact of covering the intervention on the budget of the target health 
plan (excluding other spending, see E3). This represents the differential 
between expected expenditure for the proposed intervention and cost 
savings that may result from replacement of other intervention(s) currently 
covered by the health plan. Limited to cost of intervention (e.g. acquisition 
cost) 
 
Substantial                                  Substantial 
additional                                       savings 
expenditures                          for health plan 
E2  Cost-effectiveness of 
intervention 
Ratio of the incremental cost of the proposed intervention to its incremental 
benefit. Benefit can be expressed as number of events avoided, life-years 
gained, quality-adjusted life-years gained, additional pain-free days etc. 
 
Not cost-effective          Highly cost-effective 
E3  Impact on other spending 
Impact of providing coverage for the proposed intervention on other 
expenditures (excluding intervention cost, see E1) such as hospitalization, 
specialist consultations, adverse events, long-term care, disability costs, 
lost productivity, caregiver time, equipment maintenance cost etc. 
 
Substantial additional                  Substantial 
  other spending                               savings 
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component is partly redundant with several VM compo-
nents, it was included in the VM to reflect current deci-
sionmaking practices.
The VM was then designed to be self-contained, with an
emphasis on practicality (Figure 3). It contains:
￿ A weighting scale (1 to 5) to capture the value system of
each evaluator independent of the healthcare intervention
under scrutiny; standard deviation of weights for each VM
component (Wx) among a group of evaluators can be used
to support discussion among evaluators;
￿ Synthesized evidence for the healthcare intervention
under scrutiny prepared using a standardized methodol-
ogy to minimize bias (see below);
￿ A scoring scale (0 to 3) with defined anchors and scor-
ing guidelines; it includes four scoring options to stimu-
late thought processes and avoid loss of information with
a middle score, and zero to allow for exclusion of a com-
ponent that does not bring any value (e.g., safety less than
current practice); standard deviation of scores for each VM
component (Sx) can further stimulate deliberative process
among evaluators;
￿ A comments section for decisionmakers to provide
feedback to the producers of evidence; includes a prompt
to indicate whether low score is due to data limitation,
providing a way to capture and communicate data needs;
￿ A simple MCDA linear model to capture a value esti-
mate (V) of the intervention for each evaluator:
Where
Wx is the weight for each VM component
Sx is the score for each VM component
∑Wn is the sum of all weights (i.e., for all n VM compo-
nents)
Vx is the value contribution for each VM component
An example of how a VM component is assessed is shown
in Figure 4 (I3: Improvement of efficacy/effectiveness).
The value estimate of a healthcare intervention obtained
from an individual or from a group of evaluators is
VV
W
S
n
==
∑
⎛
⎝
⎜
⎞
⎠
⎟
== ∑∑ x
x
x
x
n
x
Wn 11
Value Matrix – assessment of the intrinsic value of a healthcare intervention Figure 3
Value Matrix – assessment of the intrinsic value of a healthcare intervention.BMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
Page 8 of 16
(page number not for citation purposes)
reported in the VM Comparative Scale as a percentage of
maximum score allowing for comparison across health-
care interventions (Figure 5). Interpretation of results
requires clear understanding of the meaning of the value
estimate, including its maximum and minimum anchors.
Anchors incorporate all the dimensions captured by the
components of the VM, thus providing a broad scale for
valuing all types of interventions. Because some compo-
nents of the VM are time bound (e.g. improvement of effi-
cacy over existing intervention at a point in time), the
value estimate will change over the life cycle of the inter-
vention as new interventions are made available.
Access to evidence – synthesized and full text
Access to high level synthesized evidence is necessary to
focus the thought process on key elements of decision but
should be complemented by easy access to full text
sources for those who want to access more details.
To ensure minimally biased evidence is available to stake-
holders, a methodology was developed to synthesize this
evidence for each component of the VM (module 3). The
principal objective was to provide the information neces-
sary and sufficient to score each component with access as
needed to full text sources. A template with instructions
was developed for each component of the VM indicating
where and how to find evidence (search algorithms, bio-
medical and economic databases, registries, manufac-
turer, health technology assessment reports, Cochrane
reviews, etc.), what to report and how (i.e., standard for-
mat). For full traceability, electronic links to full text
sources were integrated into module 2.
For example, to assess "disease severity", data to be iden-
tified and reported included disease acuteness, morbidity
(disability, quality of life) and mortality, as well as disease
stages or subtypes that differentiate therapies and target
populations. Besides extracting study results, key elements
used to define their validity are also reported, such as,
number of patients included in pivotal trials, follow-up
duration for safety data, key model features for economic
evaluations and sources used for budget impact projec-
tions. For the quality of evidence cluster, quality scores for
each type of evidence are provided by criterion of quality
assessment (quality scores are obtained via an explicit
process described below), providing decisionmakers with
structured access to results and rationale of quality assess-
ment for each type of evidence.
Value Matrix – assessing Improvement of efficacy/effectiveness (component I3) Figure 4
Value Matrix – assessing Improvement of efficacy/effectiveness (component I3).BMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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Quality of evidence – Quality Matrix
The QM was designed to quantify the quality of evidence
generated for a healthcare intervention; it is grounded in
current evidentiary requirements of healthcare decision-
making bodies and derives from numerous existing tools
and instruments to assess quality of evidence. The QM
streamlines quality assessment of all types of evidence,
disentangles criteria of quality, and provides access to a
rationale for each score attributed via a deliberative proc-
ess. The QM was designed with an emphasis on practical-
ity and includes (Figure 6):
￿ Three criteria of quality assessment (columns);
￿ 12 types of evidence currently required (rows);
￿ For each cell of the QM:
 Questions or instruments based on global standards
 Prompt for evaluator to provide rationale for score
 Scoring scales
Five elements defining quality were identified and clus-
tered in three criteria (Figure 6):
￿ Q1 Adherence to the requirements established by the
decisionmaking body to which evidence is submitted;
￿ Q2: Completeness of reporting, as prescribed by report-
ing guidelines, and consistency with cited sources and
throughout the document; this criterion can be applied to
individual studies or to a high-level document (e.g., dos-
sier) that includes several studies;
￿ Q3: Relevance of evidence to the decisionmaking body
and validity of evidence, with respect to scientific stand-
ards and methodological guidelines in applicable fields of
research.
Selection of the types of evidence (12 rows of the QM,
each representing a research field, such as clinical
research, health economics, epidemiology, pathology) for
inclusion in the QM was based on an analysis of current
evidentiary requirements of over 20 decisionmaking bod-
ies worldwide [24-28,30-40,42-44,76] ensuring that all
essential requirements were covered. This analysis also
permitted creating definitions for each type of evidence
that were sufficiently detailed to standardize QM use and
support cross-jurisdictional comparability (Figure 6).
Evidence concerning the disease and its management was
broken down into three types: disease description (#1),
current treatment patterns including practices and guide-
lines (#2), and impact of new intervention on therapy
(#3). Epidemiology data included standard metrics and
risk factors (#4). Information on the new intervention was
broken down into four types: characteristics of interven-
tion (#5), efficacy and safety data obtained from clinical
trials (#6), patient reported outcomes (PRO) data (#7)
and effectiveness data from trials and registries (#8) For
the last type of evidence, identification of effectiveness
used the criteria defined by the US Agency for Healthcare
Research and Quality (AHRQ).[83] Data on current inter-
ventions that the new intervention is projected to replace
or complement was captured in a separate component
(Comparator intervention data # 9) including efficacy,
safety, PRO and effectiveness data, and characteristics.
Economic data was broken down into three types of evi-
dence: price and price justification (#10); economic eval-
uation including impact of the new intervention on
healthcare utilization and costs, and on society (#11); and
impact of reimbursing the new intervention on the health
plan budget (#12).
Value Matrix comparative scale Figure 5
Value Matrix comparative scale.
Proven safe and efficacious 
intervention to cure endemic 
severe disease resulting in 
major healthcare savings
(e.g. malaria in Africa)
Intervention for a rare disease 
with minimal improvement in 
efficacy and major safety issues, 
resulting in major increases in 
healthcare spending
Interpretation of the VM scale
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For each type of evidence contained in the QM, instruc-
tions, questions, and for the most complex types of evi-
dence, specific instruments were developed. They were
derived from current tools (e.g., GRADE, CHEC, etc.) to
streamline scoring processes across types of evidence, dis-
tinguishing criteria of quality (e.g., reporting versus valid-
ity) while keeping the whole system practical. For
example, for type of evidence "Economic evaluation", two
11-dimension instruments were developed: 1) an instru-
ment to assess the completeness and consistency of
reporting of the study; and 2) an instrument to assess the
relevance and validity of study design and results (Figure
7).
A scoring scale with defined anchors was developed and
full transparency requires that each score be justified by
the investigator. Rationale and scores are reviewed by
another investigator and validated by experts through
deliberative process until consensus is reached. Com-
ments, rationale and scores are all integrated into the QM
for full traceability. Aggregated quality scores are esti-
mated as a percentage of maximum score by criterion, by
type of evidence or for the whole QM.
Discussion
The EVIDEM framework was tailored to reflect the
thought process underlying decisionmaking and to fit the
continuum from data generation to decision to communi-
cation of decision. It supports decisionmaking and delib-
erative processes by structuring, segregating and providing
transparent access to evidence (incorporating quality
assessment), while facilitating communication about
value judgments and data needs among stakeholders.
The instruments developed to operationalize the EVIDEM
framework are rooted in existing processes and instru-
ments; however, they integrate the essential components
of decisionmaking into a comprehensive and cohesive
structure. The VM draws on the flexibility and comprehen-
siveness of MCDA while disentangling extrinsic from
intrinsic value components, and providing structured
access to the evidence on which those value judgments are
Quality Matrix – assessment of quality of evidence for a healthcare intervention Figure 6
Quality Matrix – assessment of quality of evidence for a healthcare intervention.
 
Type of evidence  Definition 
Q1: Adherence 
to requirements* 
score 
Q2: 
Completeness & 
consistency score 
Q3: Relevance 
& validity 
score 
1 Disease  information  Disease description, disease progression/duration, 
pathophysiology, clinical presentation, severity of disease 
etc 
    
2  Treatment patterns & 
guidelines 
Treatment patterns & current practices, treatment guidelines       
3  Impact of intervention on 
therapy 
Expected role of intervention, impact on healthcare system, 
place of intervention in therapy 
    
4 Epidemiology  Epidemiology of disease treated by intervention (prevalence, 
incidence, trends, sub-population etc, where applicable) and 
risk factors 
    
5  Characteristics of 
intervention  
Indication, technical characteristics (e.g., for drugs, 
pharmacology, pharmacokinetics, interactions, contra-
indications, warnings, dosing and administration & 
concomitant therapies) 
    
6 Clinical  data  Efficacy and safety data from clinical trials (published, 
unpublished, meta-analyses, reviews) and from documents 
submitted to regulatory bodies 
    
7 Effectiveness  data  Effectiveness data (naturalistic/real life trials, effectiveness 
estimates, registry requirements, etc) 
    
8  Patient reported outcomes  Patient reported outcomes for intervention including quality 
of life, satisfaction, convenience etc 
    
9 Comparator  data  Data on efficacy, safety, patient reported outcomes, 
intervention characteristics for comparators, where 
applicable 
    
10  Price information/ 
justification 
Price of intervention and comparators; price justification       
11 Economic  evaluation  Economic evaluation; impact of intervention on healthcare 
utilization and associated costs; impact on society and 
associated cost, where applicable  
 Scoring   
See Figure 7 
Scoring  
see Figure 7 
12  Budget impact   Budget impact analyses if intervention reimbursed (impact 
on health plan/drug plan) 
    
*Requirements established by the decisionmaking body  
Definition of effectiveness trial based on the AHRQ criteria  BMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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based. Unlike some earlier applications of MCDA,[69,74]
the VM does not require complicated mathematical mod-
els or computation, but rather serves as a communication
tool among and between stakeholders. Specific instru-
ments developed for the QM draw on existing instru-
ments in each respective field of research. These often
combine in one instrument dimensions pertaining to
quality of reporting and to relevance and validity of a
study (e.g., for economic evaluations[47,54,56]). QM
instruments disentangle quality of reporting (Q2 com-
pleteness and consistency) from relevance and validity
(Q3), requiring the reviewer to focus specifically on each
aspect of quality, bearing in mind that relevance and
validity require good reporting practices to be fully evalu-
ated. Because results of quality assessment are highly
dependent on the assessor, rather then on the instrument,
it was suggested by Gerkens et al,[84] that assessors
should reach a consensus on scores, which is required
when applying the QM instruments.
The EVIDEM framework needs to be tested in context, val-
idated and further developed through iterative collabora-
tive processes. In a proof of concept approach, the system
was pilot-tested using historical cases in the Canadian
context with the objective of assessing feasibility, practi-
cality and value to end users. The Canadian Value Panel
convened for the pilot study indicated that the VM with
embedded synthesized data would be highly useful as a
support for healthcare decisionmaking, to guide discus-
sion and share values among decisionmakers, at both the
policy and clinical levels, by systematically assessing
strengths and weaknesses of healthcare interventions in a
comprehensive and structured fashion.
Quality Matrix – assessing quality of economic evaluations Figure 7
Quality Matrix – assessing quality of economic evaluations.
Disease:                                                                                                      Study:  
Intervention:   
Setting: 
Completeness and consistency of reporting economic evaluation    Relevance and validity of economic evaluation 
Type of 
evidence  Question  Rationale  Score    Type of 
evidence  Question  Rationale  Score 
Economic 
evaluation 
Are all the dimensions of the economic 
evaluation reported? Is the reporting 
complete and transparent? Are estimates 
used in analysis in agreement with clinical 
literature/data? Are estimates used 
consistent with sources? 
Is information consistent across sections 
of study report/publication (abstract, 
methods, results, discussion)?  
COMPLETE SECTION BELOW  
 
1   Many gaps/ inconsistent 
2    
3    
4   Complete and consistent  
  Economic 
evaluation 
Is the study question relevant (choice 
of comparator, time horizon, patient 
population, outcome, perspective)? 
Is the design appropriate? (how close 
to real disease progression, costs 
included, strength of assumptions, 
sensitivity analyses, quality of sources 
[clinical, costs, epidemiology, utilities)? 
COMPLETE SECTION BELOW  
 
1   Low 
relevance/ 
validity 
2    
3    
4   High 
relevance/ 
validity 
  Dimension  Question  Comment      Dimension  Question  Comment 
1  Target 
population  Is the target population for this intervention defined? 
   
1  Target 
population 
Is the target population relevant (age, gender, disease stage, 
co-morbidities, etc…)? Is it comparable to the trial/study 
population in which efficacy/effectiveness data was obtained? 
Does it correspond to the actual population in which the 
treatment is envisioned to be used? 
 
2  Intervention 
and setting 
Are intervention & setting described (dose, duration, mode of delivery, 
hospital specialist, etc)? 
   
2  Intervention 
and setting 
Are assumptions/design regarding interventions (dose and 
duration, mode of delivery) & setting (hospital/community, 
country, etc) valid with respect to the indication/proposed 
coverage & clinical context? 
 
3 
Model  & 
event 
pathway 
Is the model described (model diagram/figure preferred), with details of the 
event pathway & attribution of costs to each node/part/arm/option/branch of 
the model? 
   
3  Event 
pathway 
Does the model reflect a realistic event pathway according to 
current knowledge? 
 
4  Comparator  Are comparators described? Is the rationale for comparator selection stated?      4  Comparator  Does the choice of comparators reflect current practice?   
5  Perspective  Are the perspective of analysis and its rationale stated? 
   
5  Perspective 
and costs 
Is the perspective chosen valid? Are all relevant costs 
considered (intervention, healthcare professional visits & 
procedures, hospitalization, long-term care, lab tests)? Are 
assumptions for cost selection valid? 
 
6  Type of 
analysis  
Is the type of analysis stated? Is the rationale for outcomes selection 
(effectiveness measure or utilities) stated? 
   
6  Outcome 
measures 
Are the selected outcomes measures (efficacy, safety and 
patient reported outcomes [PRO]) relevant? Are the primary 
efficacy/effectiveness measures used, and major side effects 
included? Are instruments to estimate PRO valid? Are 
assumptions for outcomes selection valid? 
 
7 
Parameters 
and 
estimates 
Are all the parameters used in the model (effectiveness data, adverse-event 
data, resource use, unit costs, health states, utilities) and their sources 
reported? Are the methodologies to obtain parameter estimates described 
(e.g., does it include currency conversion, inflation adjustments, calculation of 
transition probabilities, expert panel data, etc…)? Are all assumptions listed? 
Are estimates consistent with sources cited? 
   
7  Parameter 
estimates 
Are the sources and methods used to estimate the 
parameters solid (effectiveness data, adverse event 
probabilities, health states, PRO, utilities, resource use, unit 
costs)? Are assumptions valid? 
 
8  Time 
horizon  Is the time horizon reported? 
   
8  Time 
horizon 
Is time horizon long enough to capture all meaningful 
differences in costs and outcomes between the intervention 
and comparator? Are assumptions used valid? 
 
9  Discount 
rate  Is the discount rate reported? 
   
9  Discount 
rate  Is the recommended discount rate applied? 
 
10  Sensitivity 
analyses 
Are sensitivity analyses reported? Are rationales for selection of parameters 
and ranges used in sensitivity analyses reported? 
   
10  Sensitivity 
analyses 
Do sensitivity analyses cover the most critical parameters 
within a valid range? 
 
11  Results 
Are disaggregated results reported (cost & effectiveness per component, 
direct and indirect costs, total costs and effectiveness, incremental costs and 
effectiveness, and incremental cost-effectiveness ratios)? 
   
11  Conclusion  Are conclusions supported by results? 
 BMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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Practical use of this approach faces significant challenges.
Among these are uptake by decisionmaking bodies; this
will only happen if the new process is perceived as facili-
tating and simplifying their task, rather than adding com-
plexity. The EVIDEM framework was designed to create a
simple and practicable series of freely accessible tools that
could be easily integrated into existing processes, while
providing a common ground. In addition, integration of
EVIDEM records into a web-based collaborative database
is intended to provide a platform to all stakeholders for
easy access to high level data on evidence available for
healthcare interventions, as well as to value estimates.
Another major challenge will be the bringing together of
data producers and those who make decisions. There are
issues of trust and bias that need to be surmounted to pro-
vide the collaborative environment that this process
would need. This would permit the 360 degree transpar-
ency as envisioned by Dhalla & Laupacis.[15]
The framework was designed to be of use to a variety of
healthcare decisionmakers. Several applications are envi-
sioned (Figure 8). Retrospectively, the approach can be
used to explore the context of past decisions, assess the
quality of evidence available for a healthcare intervention
at a point in time, and validate the process in a given juris-
diction (Figure 8 – Application axis). Prospectively, it can
be used to evaluate new interventions and to maintain a
transparent record of evidence and decisions over its
entire the life cycle. Several studies assessing healthcare
decisionmaking processes in various regions of the world
have highlighted the importance of transparency and fair-
ness.[8,85,86] A number of initiatives have been imple-
mented globally to increase transparency in access to both
evidence and rationale for policy decisions. In Canada,
the Common Drug Review recently implemented a trans-
parency initiative.[87] while in the UK, the National Insti-
tute for Excellence is now providing full access to
manufacturer dossiers on their web site.[88] However,
current processes for coverage decisions are generally
organized in such a way that decision rationales cannot
easily be shared among members of the decision commit-
tee, let alone members of the public. Using an approach
such as EVIDEM to make and communicate decisions
could represent a significant step towards a more account-
able and transparent process. Better understanding of the
rationale behind decisions by all stakeholders could in
turn enhance the legitimacy and acceptability of deci-
sions.[5,14,15] Similar reasoning could apply to decision-
making at the individual level; patients and their
healthcare team could use such an explicit framework to
assist consideration of all the components of complex
decisions.
Another aspect of healthcare decisionmaking, which
requires further development, is extrinsic or system-
related value judgments (Figure 8 – application axis).
These may be critical in decisions and require focused dis-
cussion and elicitation of preferences or consensus build-
ing at the jurisdictional level. One study applying an
MCDA approach to healthcare priority-setting in Ghana
identified extrinsic factors such as 'age of target group' and
'poverty reduction' as critical factors through discussion
with stakeholders and local policymakers.[72] Research in
this area is essential to identify and structure system-
related factors in decisions, which will be easier if predi-
cated on transparent assessment of the intrinsic value of
interventions.
Several features are integrated in the EVIDEM framework
to facilitate communication between those who generate
data and those who need data to make decisions. Through
iterative processes, the framework can help define eviden-
tiary needs of decisionmakers and be used as a planning
tool for researchers and developers of new interventions,
to ensure that the data that is generated addresses the
needs explicitly defined (Figure 8 – Collaborative axis).
Knowledge transfer and exchange (KTE), an interactive
process between research users and research producers,
aims to increase the likelihood that evidence will be used
in practice and policy decisions.[89] A recent review sug-
gests that this field of research, still in its infancy, has yet
to identify KTE strategies that best support health policy
decisionmaking.[89] Finally, the EVIDEM framework can
also be used for educational purposes to explore the
thought processes underlying healthcare decisionmaking
and the concepts that define quality of evidence.
Conclusion
Healthcare decisions have to be made in the context of a
plethora of information, without easy access to all the nec-
essary information and without an explicit decisionmak-
ing framework. This often results in poor transparency
and controversial decisions. The EVIDEM framework pro-
vides a comprehensive transparent structure grounded in
global standards and local needs. The proposed frame-
work is a step to organizing evidence and streamlining
processes on a collaborative approach. This framework
should not be viewed as a formula but rather as an aid to
ensuring that all important data is considered and that
rationales and values underlying a decision may be
shared. It supports deliberative processes [12,90] allowing
decisionmakers to combine all types of evidence and val-
ues, and increases the likelihood of making solid deci-
sions. Validation and further development through
collaborative and synergistic efforts is necessary to explore
the value of this framework in practice. This type of sys-
tematized and shareable approach for data access andBMC Health Services Research 2008, 8:270 http://www.biomedcentral.com/1472-6963/8/270
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value assessment is expected to help optimize decisions,
resources, and health.
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